Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy
Authors
Keywords
Oxaliplatin, Drug accumulation, DNA repair, Survival pathways, Personalized medicine
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 77, Issue 1, Pages 5-18
Publisher
Springer Nature
Online
2015-11-20
DOI
10.1007/s00280-015-2901-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells
- (2014) Giacomo Cossa et al. CANCER LETTERS
- What do drug transporters really do?
- (2014) Sanjay K. Nigam NATURE REVIEWS DRUG DISCOVERY
- Trial watch
- (2014) Erika Vacchelli et al. OncoImmunology
- ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
- (2013) P Li et al. BRITISH JOURNAL OF CANCER
- Molecular mechanisms of ATP secretion during immunogenic cell death
- (2013) I Martins et al. CELL DEATH AND DIFFERENTIATION
- Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer:XPD-Lys751Glnpolymorphism strikes back
- (2013) Amir Avan et al. INTERNATIONAL JOURNAL OF CANCER
- Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
- (2012) Giacomo Cossa et al. CURRENT PHARMACEUTICAL DESIGN
- Polymorphic Transporters and Platinum Pharmacodynamics
- (2012) Jason A. Sprowl et al. Drug Metabolism and Pharmacokinetics
- Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin
- (2012) Marcello Tiseo et al. LUNG CANCER
- Cancer treatment according to BRCA1 and BRCA2 mutations
- (2012) Kara N. Maxwell et al. Nature Reviews Clinical Oncology
- Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells
- (2011) D Bose et al. BRITISH JOURNAL OF CANCER
- Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
- (2011) A. Zaanan et al. CLINICAL CANCER RESEARCH
- ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
- (2011) Ming Yin et al. CLINICAL CANCER RESEARCH
- A Review of Excision Repair Cross-complementation Group 1 in Colorectal Cancer
- (2011) Pierre Bohanes et al. Clinical Colorectal Cancer
- Contribution of glutathione and MRP-mediated efflux to intracellular oxaliplatin accumulation
- (2011) C. Mohn et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
- (2011) Da Yang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Oxaliplatin Transport Mediated by Organic Cation/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons
- (2011) N. N. Jong et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
- (2010) M T de Bruijn et al. BRITISH JOURNAL OF CANCER
- Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters
- (2010) C. J. Morrow et al. CANCER RESEARCH
- The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models
- (2010) S. A. Flanigan et al. CLINICAL CANCER RESEARCH
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Organic Cation Transporter 1, OCT1 in the Pharmacokinetics and Toxicity of cis-Diammine(pyridine)chloroplatinum(II) and Oxaliplatin in Mice
- (2010) Shuanglian Li et al. PHARMACEUTICAL RESEARCH
- Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy
- (2009) Dirk Theile et al. BIOCHEMICAL PHARMACOLOGY
- Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
- (2009) J Souglakos et al. BRITISH JOURNAL OF CANCER
- Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity
- (2009) Johnson J. Liu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition
- (2009) N. A. Dallas et al. CANCER RESEARCH
- Copper Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin
- (2009) B. G. Blair et al. CLINICAL CANCER RESEARCH
- Strategies to Improve the Efficacy of Platinum Compounds
- (2009) Giacomo Cossa et al. CURRENT MEDICINAL CHEMISTRY
- Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy
- (2009) Eva Martinez-Balibrea et al. INTERNATIONAL JOURNAL OF CANCER
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- ABC Transporters as Potential Targets for Modulation of Drug Resistance
- (2009) L. Gatti et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy
- (2009) J Yang et al. ONCOGENE
- ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
- (2008) H J Jun et al. BRITISH JOURNAL OF CANCER
- Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance
- (2008) E. M. Swisher et al. CANCER RESEARCH
- Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy
- (2008) M. K. Kim et al. CLINICAL CANCER RESEARCH
- Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor- B Transcription and Evasion of Apoptosis
- (2008) C. Wilson et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds
- (2008) V. Benedetti et al. MOLECULAR CANCER THERAPEUTICS
- The Role of the Mammalian Copper Transporter 1 in the Cellular Accumulation of Platinum-Based Drugs
- (2008) C. A. Larson et al. MOLECULAR PHARMACOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started